ClinicalTrials.gg
TerminatedNCT02897115STRIKEUpdated Jul 5, 2019Results posted

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

A Phase 4 interventional study of Adalimumab and Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Axial Spondyloarthritis, sponsored by AbbVie. Terminated. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated due to slow recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care [SOC]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).

02

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • Axial Spondyloarthritis
  • Humira
03

In context

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

This study's enrollment of 22 is below the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.

Browse Axial Spondyloarthritis studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written before start of study-related assessments or procedures
  • Diagnosis of axSpA (either ankylosing spondylitis or non-radiographic axSpA) and fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axSpA
  • Participants aged ≥ 18 years
  • Disease duration \< 5 years
  • Participants must have a Baseline disease activity as defined by an ASDAS ≥ 2.1 or a Bath AS Disease Activity Index (BASDAI) ≥ 4
  • NSAID-naive or not treated with the maximal recommended NSAID dose during the last 2 weeks prior to the Baseline visit
  • Participants must never have failed a NSAID taken at maximal recommended dose for 2 weeks or more.

Exclusion criteria

Exclusion Criteria:

  • for NSAIDs or tumor necrosis factor (TNF) blocker according to local labeling
  • If entering the study on concomitant NSAIDs, participants taking the maximal recommended dose during the last 2 weeks prior to the Baseline Visit or have failed or developed intolerance to a NSAID taken at maximal recommended dose for 2 weeks or more at any time
  • Prior exposure to any anti-TNF therapy; any biologic therapy with a potential therapeutic impact on SpA, or participant has been treated with any drug of chemical or biologic nature within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treat-to-Target (T2T)

    Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.

    Biological: Adalimumab

  • Active comparator
    Standard of Care (SOC)

    Participants received treatment as prescribed by their physician according to the local standard of care.

    Other: Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Interventions

  • BiologicalAdalimumab

    Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.

    Also known as: Humira, ABT-D2E7

  • OtherNon-steroidal Anti-inflammatory Drugs (NSAIDs)

    ASAS recommended NSAID doses to treat axial spondyloarthritis.

    Also known as: Routine practice

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.

    Time frame: Week 32

Secondary outcomes

  1. Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire

    The EQ-5D-3L is a health state utility instrument that evaluates preference for health status (utility). The 5 items in the EQ-5D-3L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 3 levels of severity (1: indicating no problem, 2: indicating some/moderate problems, 3: indicating extreme problems). A single preference-weighted health utility index score was calculated by applying country-specific weights, with scores ranging from approximately 0 (death) to 1 (full health).

    Time frame: Baseline, week 32, and week 52

  2. Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Presenteeism

    The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

    Time frame: Baseline, week 32, and week 52

  3. Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Absenteeism

    The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

    Time frame: Baseline, week 32, and week 52

  4. Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Work Productivity Impairment

    The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

    Time frame: Baseline, week 32, and week 52

  5. Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Activity Impairment

    The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

    Time frame: Baseline, week 32, and week 52

  6. Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)

    The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.

    Time frame: Baseline, week 32, and week 52

  7. Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.

    Time frame: Baseline, week 32, and week 52

  8. Percentage of Participants Achieving a BASDAI 50 Response

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.

    Time frame: Baseline, week 32, and week 52

  9. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 (best) to 10 (worst).

    Time frame: Baseline, week 32, and week 52

  10. Change From Baseline in ASDAS(CRP)

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." Change from baseline in ASDAS calculated using CRP is reported.

    Time frame: Baseline, week 32, and week 52

  11. Percentage of Participants Achieving ASDAS(CRP) Major Improvement

    ASDAS Major Improvement is defined as a change from baseline ≤ -2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with major improvement in ASDAS calculated using CRP is reported.

    Time frame: Baseline, week 32, and week 52

  12. Percentage of Participants Achieving ASDAS(CRP) Clinically Important Improvement

    ASDAS clinically important improvement is defined as a change from baseline ≤ -1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with clinically important improvement in ASDAS calculated using CRP is reported.

    Time frame: Baseline, week 32, and week 52

  13. Percentage of Participants With ASDAS Inactive Disease at Week 52

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.

    Time frame: Week 52

  14. Percentage of Participants With ASDAS Low Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity (defined as ASDAS \< 2.1) calculated using CRP is reported.

    Time frame: Week 32 and week 52

  15. Percentage of Participants With ASDAS Moderate Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity (defined as an ASDAS ≥ 1.3 to \< 2.1) calculated using CRP is reported.

    Time frame: Week 32 and week 52

  16. Percentage of Participants With ASDAS High Disease Activity

    ASDAS high disease activity is defined as an ASDAS ≥ 2.1 to \< 3.5. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with high disease activity (defined as an ASDAS ≥ 2.1 to \< 3.5) calculated using CRP is reported.

    Time frame: Week 32 and week 52

  17. Percentage of Participants With ASDAS Very High Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with very high disease activity (defined as an ASDAS \> 3.5) calculated using CRP is reported

    Time frame: Week 32 and week 52

  18. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

    ASAS20 response was defined as improvement of ≥ 20% relative to baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline, week 32, and week 52

  19. Percentage of Participants Achieving an ASAS 40 Response

    ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline, week 32, and week 52

  20. Percentage of Participants Achieving ASAS Partial Remission

    ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Week 32 and week 52

  21. Change From Baseline in Active Inflammation of the Sacroiliac Joints and Spine

    Active inflammation of the sacroiliac (SI) joints as well as the cervical, thoracic and lumbar regions of the spine was assessed using magnetic resonance imaging (MRI). Images were scored by a central reader according to the Berlin MRI Score on a grading scale from 0 to 3, where Grade 0 indicates no active inflammation and Grade 3 indicates \> 66% inflammation of the sacroiliac joints or \> 50% active inflammation in the spine.

    Time frame: Baseline and week 52

  22. Change From Baseline in Physician's Global Assessment of Disease Activity

    The Physician's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (severe disease activity).

    Time frame: Baseline, week 32, and week 52

  23. Change From Baseline in Patient's Global Assessment of Disease Activity

    The Patient's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (very severe disease activity).

    Time frame: Baseline, week 32, and week 52

  24. Change From Baseline in Patient's Global Assessment of Pain

    The Patient's Global Assessment of Pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).

    Time frame: Baseline, week 32, and week 52

  25. Change From Baseline in Swollen Joint Count

    An assessment of 66 joints was performed by physical examination of each joint. The swollen joint count is the number of joints assessed as swollen (0 to 66).

    Time frame: Baseline, week 32, and week 52

  26. Change From Baseline in Tender Joint Count

    An assessment of 68 joints was performed by physical examination of each joint. The tender joint count is the number of joints assessed as tender (0 to 68).

    Time frame: Baseline, week 32, and week 52

  27. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES)

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at 13 entheses (sites where tendons or ligaments insert into the bone). All sites were scored as 0 (absent) or 1 (present). The MASES is the sum of all site scores (from 0 to 13).

    Time frame: Baseline, week 32, and week 52

  28. Change From Baseline in Dactylitis Count

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as 0 for no dactylitis or 1 for dactylitis present. The dactylitis count, ranging from 0 to 20, is the total number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline, week 32, and week 52

  29. Change From Baseline in the Erythrocyte Sedimentation Rate (ESR)

    Erythrocyte sedimentation rate measures the rate of fall (sedimentation) of erythrocytes (red blood cells) in a sample of blood that has been placed into a tall, thin, vertical tube as an indirect measure of the degree of inflammation present in the body.

    Time frame: Baseline, week 32, and week 52

  30. Change From Baseline in C-reactive Protein (CRP)

    CRP is an acute phase reactant is a blood test marker for inflammation in the body. CRP levels rise in response to inflammation.

    Time frame: Baseline, week 32, and week 52

  31. Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)

    The linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin) is a composite score based on 5 direct measurements of spinal mobility: lateral lumbar flexion, tragus-to-wall distance, lumbar flexion, intermalleolar distance, and cervical rotation angle. The total score ranges from 0 to 10, where higher scores indicate more limited mobility.

    Time frame: Baseline, week 32, and week 52

  32. Number of Participants With New Onset Anterior Uveitis

    Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Up to Week 52

07

Results

Posted Jul 5, 2019

Participant flow

The study planned to enroll approximately 240 participants at 30 sites in Germany. Due to slow enrollment the study was terminated prematurely; at the time the decision to close the study was made 22 subjects were enrolled at 9 sites in Germany.

Participant flow — Overall Study
MilestoneTreat-to-Target (T2T)Standard of Care (SOC)
Started148
Completed30
Not completed118
Withdrew: Early termination of study by sponsor118

Outcome measures

PrimaryPercentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 3280.00.0
SecondaryChange From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire

The EQ-5D-3L is a health state utility instrument that evaluates preference for health status (utility). The 5 items in the EQ-5D-3L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 3 levels of severity (1: indicating no problem, 2: indicating some/moderate problems, 3: indicating extreme problems). A single preference-weighted health utility index score was calculated by applying country-specific weights, with scores ranging from approximately 0 (death) to 1 (full health).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire
units on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.446 ± 0.181-0.287 ± NA
Week 520.255 ± NA—
SecondaryChange From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Presenteeism

The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · percent impairment
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Presenteeism
percent impairmentTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-23.3 ± 55.120.0 ± NA
SecondaryChange From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Absenteeism

The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · percent impairment
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Absenteeism
percent impairmentTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-100.0 ± NA25.0 ± NA
Week 52-100.0 ± NA—
SecondaryChange From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Work Productivity Impairment

The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · percent impairment
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Work Productivity Impairment
percent impairmentTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-90.0 ± NA27.5 ± NA
Week 52-80.0 ± NA—
SecondaryChange From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Activity Impairment

The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · percent impairment
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Activity Impairment
percent impairmentTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-36.0 ± 15.230.0 ± NA
Week 52-30.0 ± NA—
SecondaryChange From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)

The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-4.00 ± 2.453.00 ± NA
Week 52-3.00 ± NA—
SecondaryChange From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-3.96 ± 1.683.20 ± NA
Week 52-1.83 ± 3.18—
SecondaryPercentage of Participants Achieving a BASDAI 50 Response

The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.

Time frame:
Baseline, week 32, and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a BASDAI 50 Response
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3260.00.0
Week 5233.3—
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 (best) to 10 (worst).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-2.46 ± 2.14-1.50 ± NA
Week 52-1.40 ± 0.849—
SecondaryChange From Baseline in ASDAS(CRP)

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." Change from baseline in ASDAS calculated using CRP is reported.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in ASDAS(CRP)
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-1.29 ± 0.833—
Week 52-0.654 ± 1.22—
SecondaryPercentage of Participants Achieving ASDAS(CRP) Major Improvement

ASDAS Major Improvement is defined as a change from baseline ≤ -2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with major improvement in ASDAS calculated using CRP is reported.

Time frame:
Baseline, week 32, and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS(CRP) Major Improvement
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3220.0—
Week 5233.3—
SecondaryPercentage of Participants Achieving ASDAS(CRP) Clinically Important Improvement

ASDAS clinically important improvement is defined as a change from baseline ≤ -1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with clinically important improvement in ASDAS calculated using CRP is reported.

Time frame:
Baseline, week 32, and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS(CRP) Clinically Important Improvement
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3260.0—
Week 5233.3—
SecondaryPercentage of Participants With ASDAS Inactive Disease at Week 52

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Inactive Disease at Week 52
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Percentage of Participants With ASDAS Inactive Disease at Week 5233.3—
SecondaryPercentage of Participants With ASDAS Low Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity (defined as ASDAS \< 2.1) calculated using CRP is reported.

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Low Disease Activity
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3280.00.0
Week 5266.7—
SecondaryPercentage of Participants With ASDAS Moderate Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity (defined as an ASDAS ≥ 1.3 to \< 2.1) calculated using CRP is reported.

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Moderate Disease Activity
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.00.0
Week 5233.3—
SecondaryPercentage of Participants With ASDAS High Disease Activity

ASDAS high disease activity is defined as an ASDAS ≥ 2.1 to \< 3.5. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with high disease activity (defined as an ASDAS ≥ 2.1 to \< 3.5) calculated using CRP is reported.

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS High Disease Activity
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3220.0100.0
Week 5233.3—
SecondaryPercentage of Participants With ASDAS Very High Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with very high disease activity (defined as an ASDAS \> 3.5) calculated using CRP is reported

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Very High Disease Activity
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.00.0
Week 520.0—
SecondaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

ASAS20 response was defined as improvement of ≥ 20% relative to baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline, week 32, and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3240.00.0
Week 5250.0—
SecondaryPercentage of Participants Achieving an ASAS 40 Response

ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline, week 32, and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ASAS 40 Response
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 3220.00.0
Week 5250.0—
SecondaryPercentage of Participants Achieving ASAS Partial Remission

ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASAS Partial Remission
percentage of participantsTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.00.0
Week 5250.0—
SecondaryChange From Baseline in Active Inflammation of the Sacroiliac Joints and Spine

Active inflammation of the sacroiliac (SI) joints as well as the cervical, thoracic and lumbar regions of the spine was assessed using magnetic resonance imaging (MRI). Images were scored by a central reader according to the Berlin MRI Score on a grading scale from 0 to 3, where Grade 0 indicates no active inflammation and Grade 3 indicates \> 66% inflammation of the sacroiliac joints or \> 50% active inflammation in the spine.

Time frame:
Baseline and week 52

No measurements were reported for this outcome.

SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity

The Physician's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (severe disease activity).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-4.00 ± 1.411.00 ± NA
Week 52-2.00 ± 3.00—
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity

The Patient's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (very severe disease activity).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Patient's Global Assessment of Disease Activity
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-2.20 ± 3.904.00 ± NA
Week 52-1.00 ± 3.61—
SecondaryChange From Baseline in Patient's Global Assessment of Pain

The Patient's Global Assessment of Pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Patient's Global Assessment of Pain
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-1.60 ± 4.283.00 ± NA
Week 52-0.333 ± 2.08—
SecondaryChange From Baseline in Swollen Joint Count

An assessment of 66 joints was performed by physical examination of each joint. The swollen joint count is the number of joints assessed as swollen (0 to 66).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · swollen joints
Change From Baseline in Swollen Joint Count
swollen jointsTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.0000 ± 0.00000.0000 ± NA
Week 520.333 ± 0.577—
SecondaryChange From Baseline in Tender Joint Count

An assessment of 68 joints was performed by physical examination of each joint. The tender joint count is the number of joints assessed as tender (0 to 68).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · tender joints
Change From Baseline in Tender Joint Count
tender jointsTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-3.40 ± 5.981.00 ± NA
Week 52-6.33 ± 6.66—
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES)

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at 13 entheses (sites where tendons or ligaments insert into the bone). All sites were scored as 0 (absent) or 1 (present). The MASES is the sum of all site scores (from 0 to 13).

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES)
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-0.800 ± 1.790.0000 ± NA
Week 520.333 ± 1.53—
SecondaryChange From Baseline in Dactylitis Count

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as 0 for no dactylitis or 1 for dactylitis present. The dactylitis count, ranging from 0 to 20, is the total number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · digits with dactylitis
Change From Baseline in Dactylitis Count
digits with dactylitisTreat-to-Target (T2T)Standard of Care (SOC)
Week 320.0000 ± 0.00000.0000 ± NA
Week 520.0000 ± 0.0000—
SecondaryChange From Baseline in the Erythrocyte Sedimentation Rate (ESR)

Erythrocyte sedimentation rate measures the rate of fall (sedimentation) of erythrocytes (red blood cells) in a sample of blood that has been placed into a tall, thin, vertical tube as an indirect measure of the degree of inflammation present in the body.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · mm/hour
Change From Baseline in the Erythrocyte Sedimentation Rate (ESR)
mm/hourTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-2.60 ± 3.050.0000 ± NA
Week 52-4.00 ± 3.46—
SecondaryChange From Baseline in C-reactive Protein (CRP)

CRP is an acute phase reactant is a blood test marker for inflammation in the body. CRP levels rise in response to inflammation.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · mg/L
Change From Baseline in C-reactive Protein (CRP)
mg/LTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-4.47 ± 4.38-1.00 ± NA
Week 52-3.47 ± 6.00—
SecondaryChange From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)

The linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin) is a composite score based on 5 direct measurements of spinal mobility: lateral lumbar flexion, tragus-to-wall distance, lumbar flexion, intermalleolar distance, and cervical rotation angle. The total score ranges from 0 to 10, where higher scores indicate more limited mobility.

Time frame:
Baseline, week 32, and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)
score on a scaleTreat-to-Target (T2T)Standard of Care (SOC)
Week 32-1.00 ± 0.632-1.10 ± NA
Week 52-1.20 ± 0.944—
SecondaryNumber of Participants With New Onset Anterior Uveitis

Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With New Onset Anterior Uveitis
ParticipantsTreat-to-Target (T2T)Standard of Care (SOC)
Number of Participants With New Onset Anterior Uveitis00

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care (SOC)0/8 (0%)0/8 (0%)6/8 (75%)
Treat-to-Target (T2T)0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Most frequent serious events
Most frequent serious events
EventStandard of Care (SOC)Treat-to-Target (T2T)
CHOLECYSTITIS CHRONICHepatobiliary disorders0/81/14
Most frequent other events
Showing 10 of 45
Most frequent other events
EventStandard of Care (SOC)Treat-to-Target (T2T)
NASOPHARYNGITISInfections and infestations3/84/14
AXIAL SPONDYLOARTHRITISMusculoskeletal and connective tissue disorders3/82/14
GASTROENTERITISInfections and infestations2/81/14
ABDOMINAL PAIN UPPERGastrointestinal disorders1/83/14
GASTRITISGastrointestinal disorders0/82/14
NAUSEAGastrointestinal disorders0/82/14
BACK PAINMusculoskeletal and connective tissue disorders0/82/14
HEADACHENervous system disorders0/82/14
TOOTHACHEGastrointestinal disorders1/80/14
CYSTITISInfections and infestations1/81/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treat-to-Target (T2T)Standard of Care (SOC)Total
Mean37.0 ± 9.4929.6 ± 7.9634.3 ± 9.49
Sex: Female, Male
Sex: Female, Male(Participants)Treat-to-Target (T2T)Standard of Care (SOC)Total
Female8412
Male6410
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Treat-to-Target (T2T)Standard of Care (SOC)Total
Count of participants——0
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Dec 2017, 15 months.

Results were first posted in Jul 2019, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2016
First posted
Sep 13, 2016
StartActual
Sep 12, 2016
Primary completionActual
Dec 21, 2017
CompletionActual
Dec 21, 2017
Results first posted
Jul 5, 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02897115
Lead sponsor
AbbVie
Collaborators
IST GmbH, Germany, Hannover Medical School, Improvement by Movement GmbH, Germany
Responsible party
Sponsor
First posted
Sep 13, 2016
Start date
Sep 12, 2016
Primary completion
Dec 21, 2017
Completion
Dec 21, 2017
Results posted
Jul 5, 2019
Last update
Jul 5, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion